Safety of biologics in severe asthmatic patients with SARS‐CoV‐2 infection: A prospective study
Pediatric Pulmonology · 2023
DOI: 10.1002/ppul.26298 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Pulmonology, 2023. Verfasst von Sara Manti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Respiratory Unit, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. Hauptthemen laut MEDLINE: COVID-19, Asthma, Biological Products. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Background
Asthma guidelines have recommended continuing treatment with biologics during coronavirus disease 2019 (COVID‐19) pandemic. However, a continuation of treatment with biologics in patients with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been little investigated.
Objective
To assess the safety of biologics in patients with SARS‐CoV‐2 infection.
Methods
A pilot, monocentric, prospective study. Patients aged 6 years old and older with severe asthma on treatment with biologics and confirmed SARS‐CoV‐2 infection were enrolled. Patients were followed‐up with periodic calls at different time points up to 3 months to detect any adverse effect and its relationship with biologic treatment according to the Naranjo Adverse Probability Scale (NAPS). The severity of SARS‐CoV‐2 infection and clinical outcome were also assessed.
Results
Overall, we included 21 patients (10 on therapy with omalizumab, 9 with dupilumab, and 2 with mepolizumab). Only a patient‐reported two local adverse events. No other adverse event was reported. Twenty out of 21 patients had a mild COVID‐19 course, and no adverse outcome was observed.
Conclusion
We showed that the scheduled dose of the biologic therapy can be administered safely on time in patients with SARS‐CoV‐2 infection, as the treatment did not result in adverse events or outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Respiratory Unit, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
- Department of Human Pathology of Adult and Childhood Gaetano Barresi, Pediatric Unit, University of Messina, Messina, Italy.
- Pediaric Unit, Maggiore Hospital, Modica, Italy.
ORCID-Profile: Sara Manti, Alessandro Giallongo, Giuseppe F Parisi
Zitieren
APA
Manti, S., Giallongo, A., Pecora, G., Parisi, G. F., Papale, M., Mulè, E., Aloisio, D., Rotolo, N., & Leonardi, S. (2023). Safety of biologics in severe asthmatic patients with SARS‐CoV‐2 infection: A prospective study. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26298
Vancouver
Manti S, Giallongo A, Pecora G, Parisi GF, Papale M, Mulè E, et al. Safety of biologics in severe asthmatic patients with SARS‐CoV‐2 infection: A prospective study. Pediatric Pulmonology. 2023. doi:10.1002/ppul.26298
BibTeX
@article{Manti2023,
author = {Manti, Sara and Giallongo, Alessandro and Pecora, Giulia and Parisi, Giuseppe F and Papale, Maria and Mulè, Enza and Aloisio, Donatella and Rotolo, Novella and Leonardi, Salvatore},
title = {Safety of biologics in severe asthmatic patients with SARS‐CoV‐2 infection: A prospective study},
journal = {Pediatric Pulmonology},
year = {2023},
doi = {10.1002/ppul.26298}
}
EUVIMED